Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17428584 | 0.74 | MMP2 (0.30) | — | |
| SCHEMBL29951534 | 0.74 | MMP2 (0.30) | — | |
| SCHEMBL26942620 | 0.74 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL19932771 | 0.69 | ALDH1A1 (0.46) | ADH1BADH1AALDH1A1SMN1; SMN2 | |
| SCHEMBL1241896 | 0.69 | ALDH1A1 (0.46) | ADH1BADH1AALDH1A1SMN1; SMN2 | |
| SCHEMBL1241894 | 0.69 | ALDH1A1 (0.46) | ADH1BADH1AALDH1A1SMN1; SMN2 | |
| SCHEMBL9006398 | 0.67 | ADH1B (0.42) | ADH1BADH1AALDH1A1 | |
| SCHEMBL18712598 | 0.67 | ADH1B (0.42) | ADH1BADH1AALDH1A1 | |
| SCHEMBL22166168 | 0.67 | ADH1B (0.42) | ADH1BADH1AALDH1A1 | |
| SCHEMBL17313812 | 0.67 | ADH1B (0.42) | ADH1BADH1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399328-A1 | DICYCLOPROPYLMETHYL DERIVATIVES AS IL-17 MODULATORS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2023-12-14 | — | — | US | disclosed |
| WO-2022096412-A1 | DICYCLOPROPYLMETHYL DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399328-A1 | DICYCLOPROPYLMETHYL DERIVATIVES AS IL-17 MODULATORS | IL17A, IL23R, IL2 | ADH1B 3621/4885ADH1A 2261/4885ALDH1A1 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.